The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment

References

• Keefe RS, Goldberg TE, Harvey PD, et al. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2–3):283–297.
   PubMed Web of Science ®Google Scholar
• Fioravanti M, Bianchi V, Cinti ME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 2012;20:12–64.
   Google Scholar
• Bora E, Binnur Akdede B, Alptekin K. Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med. 2017;47(14):2401–2413.
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Tandon R, Boutros NN, et al. Schizophrenia, “just the facts”: what we know in 2008 Part 3: neurobiology. Schizophr Res. 2008;106(2–3):89–107.
   PubMed Web of Science ®Google Scholar
• Dickinson D, Harvey PD. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull. 2009;35(2):403–414.
   PubMed Web of Science ®Google Scholar
• Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004;55(10):1013–1022.
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine and risperidone in schizophrenia. Int J Neuropsychopharm. 2005;8(3):457–472.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Fenton WS. How should DSM V criteria for schizophrenia include cognitive impairment. Schizophr Bull. 2007;33(4):912–920.
   PubMed Web of Science ®Google Scholar
• Yang YS, Marder SR1, Green MF. Repurposing drugs for cognition in schizophrenia. Clin Pharmacol Ther. 2017;101(2):191–193.
   PubMed Web of Science ®Google Scholar
• Opler LA, Medalia A, Opler MG, et al. Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectr. 2014;19(2):142–156.
   PubMed Web of Science ®Google Scholar
• Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75–83.
   PubMed Web of Science ®Google Scholar
• Berthold-Losleben M, Heitmann S, Himmerich H. Anti-inflammatory drugs in psychiatry. Inflamm Allergy Drug Targets. 2009;8(4):266–276.
   PubMedGoogle Scholar
• Orhan F, Fatouros-Bergman H, Schwieler L, et al. First-episode psychosis patients display increased plasma IL-18 that correlates with cognitive dysfunction. Schizophr Res. 2018;195:406–408.
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic review. Biol Psychiatry. 2008;63(8):801–808.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–671.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokines alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;12:1696–1709.
   Google Scholar
• Wysokiński A, Margulska A, Strzelecki D, et al. Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry. 2015;69(5):346–353.
   PubMed Web of Science ®Google Scholar
• Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155(1–3):101–108.
   PubMed Web of Science ®Google Scholar
• Gurung J, Chamlagai D, Bera NK. Elevated levels of C-reactive protein and IL-6 among the antipsychotic medicating schizophrenia patients of Siliguri, West Bengal, India. Nord J Psychiatry. 2018;72(4):311–317.
   PubMed Web of Science ®Google Scholar
• Drzyzga Ł, Obuchowicz E, Marcinowska A, et al. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006;20(6):532–545.
   PubMed Web of Science ®Google Scholar
• Romeo B, Brunet-Lecomte M, Martelli C, et al. Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis. Int J Neuropsychopharmacol. 2018;21(9):828–836.
   PubMed Web of Science ®Google Scholar
• Dasdemir S, Kucukali CI, Bireller ES, et al. Chemokine gene variants in schizophrenia. Nord J Psychiatry. 2016;70(6):407–412.
   PubMed Web of Science ®Google Scholar
• Hudson ZD, Miller BJ. Meta-analysis of cytokine and chemokine genes in schizophrenia. Clin Schizophr Relat Psychoses. 2018;12(3):121–129b.
   PubMedGoogle Scholar
• Ribeiro-Santos R, Teixeira AL, Salgado JV. Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol. 2014;12(3):273–280.
   PubMed Web of Science ®Google Scholar
• Misiak B, Stanczykiewicz B, Kotowicz K, et al. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophr Res. 2018;192:16–29.
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93(1–3):261–265.
   PubMed Web of Science ®Google Scholar
• Bulzacka E, Boyer L, Schürhoff F, et al. Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset. Schizophr Bull. 2016;42(5):1290–1302.
   PubMed Web of Science ®Google Scholar
• Johnsen E, Fathian F, Kroken RA, et al. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry. 2016;16(1):60.
   PubMedGoogle Scholar
• Fathian F, Løberg EM, Gjestad R, et al. Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. Acta Neuropsychiatr. 2019;31:36–45.
   PubMed Web of Science ®Google Scholar
• Aas M, Dazzan P, Mondelli V, et al. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front Psychiatry. 2014;4:182.
   PubMed Web of Science ®Google Scholar
• Cabrera B, Bioque M, Penadés R, et al. Cognition and psychopathology in first-episode psychosis: are they related to inflammation? Psychol Med. 2016;46(10):2133–2144.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley PF, McEvoy JP. Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res. 2018;195:275–282.
   PubMed Web of Science ®Google Scholar
• Martínez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res. 2012;137(1–3):66–72.
   PubMed Web of Science ®Google Scholar
• De Campos-Carli SM, Miranda AS, Dias ICS, et al. Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia. Compr Psychiatry. 2017;74:96–101.
   PubMed Web of Science ®Google Scholar
• Kogan S, Ospina LH, Kimhy D. Inflammation in individuals with schizophrenia – implications for neurocognition and daily function. Brain Behav Immun. 2018;74:296–299.
   PubMed Web of Science ®Google Scholar
• Amorim P. Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Rev Bras Psiquiatr. 2000;22(3):106–115.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Bressan RA, Chaves AC, Shirakawa I, et al. Validity study of the Brazilian version of the calgary depression scale for schizophrenia. Schizophr Res. 1998;32(1):41–49.
   PubMed Web of Science ®Google Scholar
• Tonelli H, Tonelli D, Poiani GR, et al. Reliability and clinical utility of a Portuguese version of the abnormal involuntary movements scale (AIMS) for tardive dyskinesia in Brazilian patients. Braz J Med Biol Res. 2003;36(4):511–514.
   PubMed Web of Science ®Google Scholar
• Knol W, Keijsers CJ, Jansen PA, et al. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol. 2010;30(1):57–63.
   PubMed Web of Science ®Google Scholar
• Araújo GE, Resende CB, Cardoso AC, et al. Validity and reliability of the Brazilian Portuguese version of the BACS (brief assessment of cognition in schizophrenia). Clinics (Sao Paulo). 2015;70(4):278–282.
   PubMed Web of Science ®Google Scholar
• Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686–693.
   PubMed Web of Science ®Google Scholar
• Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236–1238.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee DK. What is the proper way to apply the multiple comparison test? Korean J Anesthesiol. 2018;71(5):353–360.
   PubMed Web of Science ®Google Scholar
• Ganguli R, Yang Z, Shurin G, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 1994;51(1):1–10.
   PubMed Web of Science ®Google Scholar
• Na KS, Kim YK. Monocytic, Th1 and Th2 cytokinealterations in the pathophysiology of schizophrenia. Neuropsychobiology. 2007;56(2–3):55–63.
   PubMed Web of Science ®Google Scholar
• Chiang SS, Riedel M, Schwarz M, et al. Is T-helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls. Psychiatry Clin Neurosci. 2013;67(4):228–236.
   PubMed Web of Science ®Google Scholar
• Wei J, Xu H, Davies JL, et al. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci. 1992;51(25):1953–1956.
   PubMed Web of Science ®Google Scholar
• Tourjman V, Kouassi É, Koué MÈ, et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res. 2013;151(1–3):43–47.
   PubMed Web of Science ®Google Scholar
• Frydecka D, Misiak B, Pawlak-Adamska E, et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci. 2015;265(6):449–459.
   PubMed Web of Science ®Google Scholar
• Fillman SG, Weickert TW, Lenroot RK, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume. Mol Psychiatry. 2016;21(8):1090–1098.
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Katsuki A, et al. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World J Biol Psychiatry. 2017;18(5):401–408.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Tan YL, Chen DC, et al. Interaction of BDNF with cytokines in chronic schizophrenia. Brain Behav Immun. 2016;51:169–175.
   PubMed Web of Science ®Google Scholar
• Zhang X, Soares J. Interaction of cortisol and cytokines in chronic patients with schizophrenia: relationship to psychopathology and cognition. Biol Psychiatry. 2017;81(10):126.
   Web of Science ®Google Scholar
• Hope S, Hoseth E, Dieset I, et al. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res. 2015;165(2–3):188–194.
   PubMed Web of Science ®Google Scholar
• Ergün S, Yanartaş O, Kandemir G, et al. The relationship between psychopathology and cognitive functions with cytokines in clinically stable patients with schizophrenia. Psych Clin Psychopharmacology. 2018;28(1):66–72.
   Web of Science ®Google Scholar
• Kubistova A, Horacek J, Novak T. Increased interleukin-6 and tumor necrosis alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub. 2012;(Suppl.1):S153–S156.
   PubMedGoogle Scholar
• Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106–114.
   PubMed Web of Science ®Google Scholar
• Marsland AL, Gianaros PJ, Abramowitch SM, et al. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry. 2008;64(6):484–490.
   PubMed Web of Science ®Google Scholar
• Van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64(9):820–822.
   PubMed Web of Science ®Google Scholar
• Van der Doef TF, Bossong MG, Boellard R, et al. Microglial activation in schizophrenia. NeuroImage. 2010;52 (suppl.1):S145.
   Google Scholar
• Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63(3):257–265.
   PubMed Web of Science ®Google Scholar
• Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006;27(2):71–80.
   PubMed Web of Science ®Google Scholar
• Fischer EK, Drago A. A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia. J Neural Transm. 2017;124(7):765–774.
   PubMed Web of Science ®Google Scholar
• Palta P, Xue QL, Deal JA, et al. Interleukin-6 and C-reactive protein levels and 9-year cognitive decline in community-dwelling older women: the women's health and aging study II. J Gerontol A Biol Sci Med Sci. 2015;70(7):873–878.
   PubMed Web of Science ®Google Scholar
• Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47(3):401–406.
   PubMed Web of Science ®Google Scholar